IceCure Medical (ICCM) said Monday that it has received a notice of allowance from the China National Intellectual Property Administration for its cryogenic system connector invention.
The notice follows grants for the same patent in the US, Europe, and Japan, the company said.
The company said its novel cryogenic pump is submersible in liquid nitrogen and is designed to be used for multiple procedures or longer duration procedures without the need to refill.
IceCure said it develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors by freezing, as an alternative to surgical tumor removal.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。